Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer
Verastem Oncology developed its drug combination for low-grade serous ovarian cancer (LGSOC) driven by KRAS mutations. As the first treatment specifically approved for this rare cancer, clinicians expect it will become the new standard of care.